Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 10, 2020, by Xenetic Biosciences, Inc., a Nevada corporation. The report details a material definitive agreement entered into on December 10, 2020, regarding a registered direct offering of common stock. The offering officially closed on December 14, 2020.
Key Financial Metrics
- Gross Proceeds: Approximately $6.0 million.
- Shares Issued: 2,448,980 shares of common stock.
- Offering Price: $2.45 per share.
- Placement Agent Fees: 7.0% of aggregate gross proceeds (approximately $420,000).
- Other Expenses: $65,000 non-accountable expense allowance and $12,900 in clearing expenses.
- Net Proceeds: Not explicitly stated in the filing text; calculated as gross proceeds less fees and expenses.
Note: This filing does not provide data on revenue, operating profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital through the issuance of 2,448,980 new shares. This transaction increases the company's cash position by approximately $6.0 million (gross) and results in immediate dilution to existing shareholders. The filing does not provide comparative financial data to prior periods.
Guidance, Outlook, and Restrictions
The filing does not contain updated financial guidance or management commentary on future operational outlook. However, the Securities Purchase Agreement includes specific covenants:
- Variable Rate Transactions: The Company is prohibited from conducting certain variable rate transactions for six months following the closing of the offering, subject to exceptions.
- Issuance Restrictions: From the date of the agreement until 15 days after closing, the Company was restricted from issuing or announcing the issuance of any additional common stock.
- Placement Agent Rights: H.C. Wainwright & Co., LLC was engaged as the exclusive placement agent with a 6-month tail and a 6-month right of first refusal.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to calculate dilution impact.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the variable rate transaction prohibition.
- Confirm the use of proceeds in subsequent filings (e.g., 10-Q or 10-K) to ensure alignment with capital needs.
- Monitor the 6-month right of first refusal period for the placement agent regarding future capital raises.